---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-009780"
form_type: "8-K"
ticker: "ICU"
cik: "0001831868"
company_name: "SeaStar Medical Holding Corp"
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T09:03:29.587301+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SeaStar Medical Q4 2025 revenue $420K; net loss narrows to $2.9M; cash grows to $12M

## Summary
- Net revenue Q4 2025 $420K (vs $67K Q4 2024); full year $1.2M (vs $135K).
- Net loss Q4 2025 $2.9M ($0.80/share) vs $4.4M ($8.98/share) Q4 2024; cash $12.0M (up from $1.8M).
- QUELIMMUNE expanded to 16 children's hospitals; SAVE Registry enrollment completed (50 patients).
- NEUTRALIZE-AKI trial >50% enrolled (181/339); modular PMA submission for adult AKI initiated.
- Guides 2026 net product revenue ~$2M; plans to add 15 more hospital sites.

## SEC filing metadata
- accession: 0001437749-26-009780
- form_type: 8-K
- ticker: ICU
- cik: 0001831868
- company_name: SeaStar Medical Holding Corp
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831868/000143774926009780/0001437749-26-009780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831868/000143774926009780/icu20260313_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-009780
- JSON: https://secwatch.observer/filing/0001437749-26-009780.json
- Plain text: https://secwatch.observer/filing/0001437749-26-009780.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.